Rangeley Capital’s Nektar Therapeutics NKTR Stock Holding History

Rangeley Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,895	Closed	-$279K	–	150
2025 Q3	$279K	Buy	+4,895	New	+$162K	0.24%	74

Other funds holding NKTR

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rangeley Capital's NKTR Position: Q4 2025 in Review

Rangeley Capital sold out of Nektar Therapeutics (NKTR) in Q4 2025, closing a stake of 4,895 shares — an estimated $279K sold.

Rangeley Capital first reported a position in NKTR in Q3 2025 and held it in 1 quarter. The position peaked at $279K in Q3 2025. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

Rangeley Capital reported no remaining Nektar Therapeutics position as of Q4 2025 after selling out during the quarter.
Rangeley Capital sold 4,895 Nektar Therapeutics shares in Q4 2025, an estimated $279K.
Rangeley Capital first reported a position in Nektar Therapeutics in Q3 2025 and held it in 1 quarter.
Rangeley Capital's Nektar Therapeutics position peaked at $279K in Q3 2025.
180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on Rangeley Capital's 13F filing for Q4 2025, filed 17 Feb 2026.